Evidence map›Paper›PMID 35731142›Full record

ArticleRheumatology (Oxford, England)2023

Upregulated expression of FFAR2 and SOC3 genes is associated with gout.

Oliver C Orji, Maria B López-Domínguez, Gabriela Sandoval-Plata, Tamar Guetta-Baranes, Ana M Valdes, Michael Doherty, Kevin Morgan, Abhishek Abhishek

Open access · hybridAbstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Epigenetic and Metabolic Regulation of Macrophages during Gout.Gout, urate, and crystal deposition disease · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Oliver C OrjiHuman Genetics, School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.ORCID 0000-0002-3285-8242
Maria B López-DomínguezHuman Genetics, School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
Gabriela Sandoval-PlataHuman Genetics, School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
Tamar Guetta-BaranesHuman Genetics, School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
Ana M ValdesAcademic Rheumatology, School of Medicine, Nottingham City Hospital, University of Nottingham.
Michael DohertyAcademic Rheumatology, School of Medicine, Nottingham City Hospital, University of Nottingham.
Kevin MorganHuman Genetics, School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
Abhishek AbhishekAcademic Rheumatology, School of Medicine, Nottingham City Hospital, University of Nottingham.ORCID 0000-0003-0121-4919
University of Nottingham · GBUniversity of Nigeria · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo examine the expression of Free fatty acid receptor 2 (FFAR2) and Suppressor of cytokine signalling 3 (SOCS3) genes in asymptomatic hyperuricaemia (AH), AH with MSU crystal deposition, inter-critical gout and gout flare.

methodsStudy participants (n = 120) comprised 34 people with serum urate (SU) <360 μmol/l, 69 with AH ± MSU crystal deposition and 17 with a gout flare. Sixteen of the 17 patients with a gout flare attended a second visit 6-12 weeks later. Gene expression levels were assessed using RT-qPCR and results computed as fold changes (FC) after normalization to the reference gene.

resultsFFAR2 was significantly upregulated during gout flares (FC = 2.9) compared with normal SU, AH, and AH + MSU crystal deposition (FC = 1.1, P < 0.0001 for each comparison). FFAR2 was also significantly upregulated during inter-critical gout (FC = 1.8) compared with normal SU, AH and AH + MSU (FC = 1.1, P < 0.001 for each comparison). SOCS3 was significantly upregulated during gout flares (FC = 3.4) compared with normal SU, AH, and AH + MSU crystal deposition (FC = 1.1, 1.1 and 1.2, respectively, P < 0.0001 for each comparison). SOCS3 was also upregulated during inter-critical gout (FC = 2.1) compared with normal SU (P = 0.02) and AH (P = 0.006) (FC = 1.1 and 1.2, respectively). FFAR2 expression was upregulated during gout flare compared with inter-critical gout and SOCS3 expression showed negative correlation with flare duration (r = -0.49, P < 0.05).

conclusionFFAR2 upregulation is associated with gout and may trigger gout flares. SOCS3 may have a role in amelioration of gout flares.

Indexed as

GoutHyperuricemiaCytokinesHumansSymptom Flare UpUric AcidCytokinesUric AcidFFAR2gene expressiongoutSOCS3

Identifiers

PMID35731142
PMCPMC9891400
OpenAlexW4283322195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.